GAM
CLDX icon

Gotham Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Gotham Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,448
Closed -$243K – 1332
2022
Q4 		$243K Buy
+5,448
New +$194K 0.01% 1091
2021
Q4 		– Sell
-12,946
Closed -$699K – 1150
2021
Q3 		$699K Buy
+12,946
New +$607K 0.03% 568
2015
Q2 		– Sell
-2,348
Closed -$982K – 929
2015
Q1 		$982K Buy
+2,348
New +$840K 0.01% 604

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Gotham Asset Management's CLDX Position: Q1 2023 in Review

Gotham Asset Management sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 5,448 shares — an estimated $243K sold.

Gotham Asset Management first reported a position in CLDX in Q1 2015 and held it in 3 quarters. The position peaked at $982K in Q1 2015. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • Gotham Asset Management reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Gotham Asset Management sold 5,448 Celldex Therapeutics shares in Q1 2023, an estimated $243K.
  • Gotham Asset Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 3 quarters.
  • Gotham Asset Management's Celldex Therapeutics position peaked at $982K in Q1 2015.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on Gotham Asset Management's 13F filing for Q1 2023, filed 15 May 2023.